{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:00:35Z","timestamp":1793383235408,"version":"4.5.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"30","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Mantle cell lymphoma (MCL) exhibits a heterogenous clinical course. The MCL International Prognostic Index (MIPI) is the most commonly used risk classification system in MCL. However, it does not contain a parameter associated with the tumor microenvironment. The aim of this study was to develop a more powerful prognostic index by evaluating the absolute monocyte count (AMC), neutrophil\/lymphocyte ratio (NLR), and platelet\/lymphocyte ratio (PLR) at diagnosis in conjunction with the clinical and laboratory parameters.<\/jats:p>\n            <jats:p>The data of 96 MCL patients with newly diagnosed from January 2014 to December 2018 were retrospectively evaluated in this study. The AMC, NLR, and PLR cut-off values were determined using the receiver operating characteristic (ROC) analysis.<\/jats:p>\n            <jats:p>The clinical behavior and results of the disease exhibited significant variation in high and low value groups at the time of diagnosis. In univariate analysis, the AMC \u2265 580, NLR \u2265 2.43, and PLR \u2265 120.85 were determined as negative prognostic factors for 5-year progression free survival (PFS) (AMC: PFS, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .001; NLR: PFS, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .001; PLR: PFS, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .001) and for 5-year overall survival (OS) (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .001, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .001, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .001, respectively). Beta-2 microglobulin (B2-MG), and MIPI for PFS, and for OS were found to be independent risk factors in the multivariate analysis (for PFS: <jats:italic toggle=\"yes\">P<\/jats:italic> = .006, <jats:italic toggle=\"yes\">P<\/jats:italic> = .002, respectively; and for OS: <jats:italic toggle=\"yes\">P<\/jats:italic> = .007, <jats:italic toggle=\"yes\">P<\/jats:italic> = .001, respectively). The 5-year OS was 20% in the group with B2-MG \u2265 3.5. The patients in high-risk MIPI group had poorer 5-year OS (median OS: 40 months, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .001).<\/jats:p>\n            <jats:p>The results stated that the use of B2-MG in conjunction with MIPI was a more sensitive method in determining the prognosis in MCL (median OS: 12 months in high-risk MIPI group with a B2-MG \u22653.5, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .001). Additionally, it was found that parameters reflecting the tumor microenvironment such as AMC, NLR, and PLR increased the risk of progression in MCL. In view of these findings, in addition B2-MG to the MIPI to create a more sensitive prognostic scoring system may provide an insight into personalization of treatment with early recognition of patients with poor prognosis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000016180","type":"journal-article","created":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T07:04:29Z","timestamp":1564124669000},"page":"e16180","source":"Crossref","is-referenced-by-count":9,"title":["Can the prognosis of mantle cell lymphoma be predicted by simple CBC counts?"],"prefix":"10.1097","volume":"98","author":[{"given":"Handan","family":"Haydaroglu Sahin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.23608","article-title":"Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004","volume":"113","author":"Zhou","year":"2008","journal-title":"Cancer"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1182\/blood-2014-03-559930","article-title":"Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study","volume":"124","author":"Abrahamsson","year":"2014","journal-title":"Blood"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"J Clin Oncol"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1182\/blood-2011-12-400580","article-title":"Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma","volume":"119","author":"Nygren","year":"2012","journal-title":"Blood"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood-2017-07-797019","article-title":"Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network","volume":"131","author":"Aukema","year":"2018","journal-title":"Blood"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/his.12760","article-title":"MYC overexpression correlates with MYC amplification or translocation, and is associated with poor prognosis in mantle cell lymphoma","volume":"68","author":"Choe","year":"2016","journal-title":"Histopathology"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-12-1615","article-title":"Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11expression have distinct biologic and clinical features","volume":"72","author":"Navarro","year":"2012","journal-title":"Cancer Res"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced- stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1365-2559.2011.04096.x","article-title":"Tumour-associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group","volume":"60","author":"Wada","year":"2012","journal-title":"Histopathology"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.3109\/10428194.2013.879713","article-title":"An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone","volume":"55","author":"Nam","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/hon.2188","article-title":"Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma","volume":"34","author":"Yoo","year":"2016","journal-title":"Hematol Oncol"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/bjh.13486","article-title":"Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan","volume":"170","author":"Chihara","year":"2015","journal-title":"Br J Haematol"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10555-006-9001-7","article-title":"Role of tumor- associated macrophages in tumor progression and invasion","volume":"25","author":"Mantovani","year":"2006","journal-title":"Cancer Metastasis Rev"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/nrc2444","article-title":"The role of myeloid cells in the promotion of tumour angiogenesis","volume":"8","author":"Murdoch","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"e017904","DOI":"10.1136\/bmjopen-2017-017904","article-title":"Prognostic value of lymphocyte-to-monocyte ratio and neutrophil- to-lymphocyte ratio in follicular lymphoma: a retrospective cohort study","volume":"7","author":"Lee","year":"2017","journal-title":"BMJ Open"},{"key":"R17-20230914","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12288-016-0720-9","article-title":"The lymphocyte-monocyte ratio and the platelet-lymphocyte ratio at diagnosis as independent prognostic factors in primary gastrointestinal diffuse large B cell lymphoma","volume":"33","author":"Zhao","year":"2017","journal-title":"Indian J Hematol Blood Transfus"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/leu.2011.112","article-title":"The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma","volume":"25","author":"Wilcox","year":"2011","journal-title":"Leukemia"},{"key":"R19-20230914","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3109\/10428194.2011.637211","article-title":"The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma","volume":"53","author":"Wilcox","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"R20-20230914","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/bjh.12409","article-title":"Prognostic impact of monocyte count at presentation in mantle cell lymphoma","volume":"162","author":"von Hohenstaufen","year":"2013","journal-title":"Br J Haematol"},{"key":"R21-20230914","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/hon.2106","article-title":"Absolute monocyte count predicts overall survival in mantle cell lymphomas: correlation with tumour-associated macrophages","volume":"32","author":"Koh","year":"2014","journal-title":"Hematol Oncol"},{"key":"R22-20230914","first-page":"1601","article-title":"Clinical Characteristics and Prognosis of 34 Patients with Mantle Cell Lymphoma: a retrospective analysis","volume":"23","author":"Chen","year":"2015","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"R23-20230914","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/bjh.12683","article-title":"Prognostic impact of monocyte count at presentation in mantle cell lymphoma","volume":"164","author":"George","year":"2014","journal-title":"Br J Haematol"},{"key":"R24-20230914","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/bjh.15054","article-title":"Pre-treatment neutrophil\/lymphocyte ratio and platelet\/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma","volume":"180","author":"Reddy","year":"2018","journal-title":"Br J Haematol"},{"key":"R25-20230914","doi-asserted-by":"crossref","first-page":"e12678","DOI":"10.1097\/MD.0000000000012678","article-title":"Prognostic value of neutrophil to lymphocyte ratio and clinicopathological characteristics for multiple myeloma: A meta-analysis","volume":"97","author":"Zeng","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"R26-20230914","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.semcancer.2005.07.005","article-title":"Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression","volume":"16","author":"Serafini","year":"2006","journal-title":"Semin Cancer Biol"},{"key":"R27-20230914","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2010-05-283820","article-title":"Immunosuppressive CD14 + HLA-DRlow\/monocytes in B-cell non-Hodgkin lymphoma","volume":"117","author":"Lin","year":"2011","journal-title":"Blood"},{"key":"R28-20230914","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.e19030","article-title":"Prognostic value of the absolute lymphocyte to monocyte (ALC\/AMC) ratio on overall survival among patients with mantle cell lymphoma","volume":"35","author":"Goy","year":"2017","journal-title":"J Clin Oncol"},{"key":"R29-20230914","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1182\/blood-2009-05-220111","article-title":"Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells","volume":"114","author":"Wilcox","year":"2009","journal-title":"Blood"},{"key":"R30-20230914","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrc3004","article-title":"Contribution of platelets to tumour metastasis","volume":"11","author":"Gay","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"R31-20230914","first-page":"5325","article-title":"Novel prognostic scoring system for diffuse large B-cell lymphoma","volume":"15","author":"Zhao","year":"2018","journal-title":"Oncol Lett"},{"key":"R32-20230914","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s12032-014-0318-8","article-title":"A prognostic model based on pretreatment platelet lymphocyte ratio for stage IE\/IIE upper aerodigestive tract extranodal NK\/T cell lymphoma, nasal type","volume":"31","author":"Wang","year":"2014","journal-title":"Med Oncol"},{"key":"R33-20230914","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1158\/1078-0432.CCR-08-0793","article-title":"Beta2-microglobulin signaling blockade inhibited androgen receptor axis and caused apoptosis in human prostate cancer cells","volume":"14","author":"Huang","year":"2008","journal-title":"Clin Cancer Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201907260-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T21:37:58Z","timestamp":1694727478000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201907260-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":33,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000016180","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}